Latest news
Business Update
Innosuisse-Funded Alzheimer’s Clinical Trial with MIAMIND®
The MIAMIND® electrical neurostimulator will be evaluated in a randomized, sham-controlled clinical trial in patients with early-stage Alzheimer’s disease (AD), supported by funding from Innosuisse.
08 April, 2026
Read more
Business Update | Fri 03, 2024
MINDSTIM study has successfully concluded
Our first clinical trial, MINDSTIM has successfully concluded!
Business Update | Mon 03, 2024
Start of the intervention phase of the MINDSTIM study
Our very first devices are now complete and ready for the intervention phase of the MINDSTIM clinical trial with our personalized neurostimulator at t
Publication | Tue 01, 2024
Bottneuro publishes Whitepaper
Read more about the technology, our customized Miamind® Neurostimulator and the opportunity the recent registration at Swissmedic and MHRA offers in o
Business Update | Thu 01, 2024
The MINDSTIM clinical trial officially started!
A new year, another Milestone in Bottneuro’s journey to develop a non-invasive Alzheimer’s Disease therapy. The MINDSTIM clinical trial officially sta
Featured news
Bottneuro Team
Dr Antonella Santuccione Chadha joins the Board of Directors at Bottneuro
02 June, 2025
